Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Retained Earnings (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Retained Earnings for 8 consecutive years, with -$628.8 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 19.56% to -$628.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$628.8 million through Dec 2025, down 19.56% year-over-year, with the annual reading at -$605.7 million for FY2025, N/A changed from the prior year.
  • Retained Earnings for Q4 2025 was -$628.8 million at Outlook Therapeutics, down from -$605.7 million in the prior quarter.
  • The five-year high for Retained Earnings was -$525.9 million in Q4 2024, with the low at -$628.8 million in Q4 2025.